Table 5.
Comparison of Current Findings From GWTG‐HF With PIONEER‐HF
| Patient Characteristics | GWTG‐HF | PIONEER‐HF3 | ||
|---|---|---|---|---|
| 9408 Patients From 301 US Sites | 887 Patients From 129 US Sites | |||
| Sacubitril/Valsartan (n=1551) | ACEI/ARB (n=7857) | Sacubitril/Valsartan (n=440) | ACEI (n=441) | |
| Age | 78 (72–84) | 78 (71–85) | 61 (51–71) | 63 (54–72) |
| Women | 630 (40.6) | 3187 (40.6) | 113 (25.7) | 133 (30.2) |
| Black race | 187 (12.2) | 968 (12.3) | 158 (35.9) | 158 (35.8) |
| Systolic blood pressure, mm Hg | 118 (106–130) | 118 (106–131) | 118 (110–133) | 118 (109–132) |
| Heart rate, beats/min | 75 (68–84) | 75 (67–84) | 81 (72–92) | 80 (72–91) |
| Creatinine, mg/dL | 1.2 (1.0–1.5) | 1.2 (0.9–1.5) | 1.3 (1.1–1.5) | 1.3 (1.1–1.5) |
| Prior PCI | 400 (26.1) | 1953 (24.8) | 2 (0.5) | 6 (1.4) |
| Prior CABG | 427 (27.9) | 2070 (26.3) | 18 (4.1) | 17 (3.9) |
| Diabetes mellitus | 650 (42.5) | 3267 (41.5) | 79 (18.0) | 89 (20.2) |
| Atrial fibrillation | 638 (41.7) | 3365 (42.8) | 147 (33.4) | 165 (37.4) |
| Relative Risk of Clinical Outcomes—Sacubitril/Valsartan vs RASi—HR (95% CI) | ||
|---|---|---|
| End Point | 12‐mo Follow‐Up | 8‐wk Follow‐Up |
| All‐cause mortality | 0.82 (0.72–0.94)* | 0.66 (0.30–1.48) |
| HF hospitalization | 1.04 (0.91–1.18)* | 0.56 (0.37–0.84) |
Data presented as n (%) or median (25th–75th percentile). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; GWTG‐HF, Get With The Guidelines–Heart Failure registry; PCI, percutaneous coronary intervention; PIONEER‐HF, Comparison of Sacubitril–Valsartan Versus Enalapril on Effect on NT‐proBNP [N‐terminal pro‐B‐type natriuretic peptide] in Patients Stabilized from an Acute Heart Failure Episode; and RASi, renin‐angiotensin system inhibitor.
Reflects full model incorporating inverse probability of treatment weighting for 25 demographic and clinical variables and 6 index hospital variables, as well as adjustment for discharge prescription for beta‐blocker and mineralocorticoid receptor antagonist therapy.